MUSK (O15146) variants and mutations
MUSK (also known as O15146) is a human protein-coding gene encoding a muscle, skeletal receptor tyrosine-protein kinase protein. It organizes the postsynaptic neuromuscular junction by responding to agrin-LRP4 signaling and clustering acetylcholine receptors. Biallelic pathogenic variants cause congenital myasthenic syndrome, while autoantibodies against MuSK cause an important subtype of acquired myasthenia gravis. This analysis covers 1,398 MUSK variants and mutations. Of these, 93% have computational variant effect predictions. Disease context includes Congenital myasthenic syndromes, fetal akinesia deformation sequence 1, and congenital myasthenic syndrome 9. Example MUSK variants include M1T, R2S, and R2T.
Variant analysis overview
- Gene: MUSK
- Protein: O15146
- UniProt accession: O15146
- Organism: Homo sapiens
- Variants analyzed: 1398
- Variant scope: all variants
- Completed: 2026-08-22
Variant and mutation evidence
- Variant composition: 1,128 unspecified-consequence records; 158 missense variants; 3 in-frame deletions; 80 synonymous variants; 16 frameshift variants; 3 splice-region variants; 8 stop-gained variants; 2 in-frame insertions
- Prediction scores: 1,297 variants have prediction scores (93% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: Congenital myasthenic syndromes, fetal akinesia deformation sequence 1, congenital myasthenic syndrome 9, fetal akinesia deformation sequence, Postsynaptic congenital myasthenic syndromes, postsynaptic congenital myasthenic syndrome, Abnormality of limbs, Respiratory insufficiency, Delayed gross motor development, Stridor, Bilateral ptosis, diabetes mellitus.
Protein structure and variant hotspots
- Protein features: 1 transmembrane segments; 5 domains; 2 binding sites; 6 post-translational modification sites.
- Structural context: 1,157 variants have structural context.
- PTM context: 10 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable MUSK variants
Examples include M1T, R2S, R2T, E3G, E3K, E3Q, E3V, L4F. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- M1T (p.Met1Thr), rs1416057660, ClinGen CA374667961, ClinVar RCV003796367, ClinVar RCV005001446, MetaLR 0.55, MetaSVM 0.20, Pathogenic, Congenital myasthenic syndrome 9; Fetal akinesia deformation sequence 1; not pro
- R2S (p.Arg2Ser), gnomAD rs2075922199, REVEL 0.21, MetaLR 0.25
- R2T (p.Arg2Thr), gnomAD 9-110668909-G-C, REVEL 0.18, MetaLR 0.23
- E3G (p.Glu3Gly), gnomAD rs1348994906, REVEL 0.30, MetaLR 0.27
- E3K (p.Glu3Lys), rs762340994, ClinGen CA5183889, cosmic curated COSV51887, ClinVar RCV002638254, REVEL 0.20, MetaLR 0.26, Uncertain significance, Inborn genetic diseases; Fetal akinesia deformation sequence 1; Congenital myast
- E3Q (p.Glu3Gln), ExAC rs762340994, TOPMed rs762340994, gnomAD rs762340994, REVEL 0.19, MetaLR 0.31, Uncertain significance
- E3V (p.Glu3Val), gnomAD 9-110668912-A-T, REVEL 0.23, MetaLR 0.20
- L4F (p.Leu4Phe), gnomAD rs1230669359, MetaLR 0.21, MetaSVM -0.89
- L4P (p.Leu4Pro), gnomAD 9-110668915-T-C, REVEL 0.20, MetaLR 0.20
- L4L (p.Leu4Leu), rs374456998, gnomAD 9-110668916-C-T, CADD 6.69
- V5A (p.Val5Ala), Ensembl rs2131614491, MetaLR 0.30, MetaSVM -0.52
- V5I (p.Val5Ile), rs765874906, ClinGen CA5183891, NCI-TCGA Cosmic COSV5188, cosmic curated COSV51885, REVEL 0.04, MetaLR 0.17, Uncertain significance, Congenital myasthenic syndrome 9; Fetal akinesia deformation sequence 1
- V5L (p.Val5Leu), ExAC rs765874906, TOPMed rs765874906, gnomAD rs765874906, REVEL 0.04, MetaLR 0.13, Uncertain significance
- V5del (p.Val5del), gnomAD 9-110668914-CTCG-, CADD 19.10
- V5D (p.Val5Asp), gnomAD 9-110668918-T-A, REVEL 0.42, MetaLR 0.35
- N6D (p.Asn6Asp), TOPMed rs1587867708, REVEL 0.04, MetaLR 0.15
- N6S (p.Asn6Ser), rs747203404, ClinGen CA5183892, ClinVar RCV001053074, ExAC rs747203404, REVEL 0.16, MetaLR 0.22, Uncertain significance, Congenital myasthenic syndrome 9; Fetal akinesia deformation sequence 1
- N6Y (p.Asn6Tyr), NCI-TCGA TCGA novel, MetaLR 0.26, MetaSVM -0.65, Variant assessed as somatic; moderate impact.
- N6H (p.Asn6His), gnomAD 9-110668920-A-C, REVEL 0.20, MetaLR 0.28
- N6K (p.Asn6Lys), gnomAD 9-110668922-C-A, REVEL 0.09, MetaLR 0.21
- I7L (p.Ile7Leu), TOPMed rs1203437880, gnomAD rs1203437880, REVEL 0.19, MetaLR 0.19
- I7T (p.Ile7Thr), rs2075922654, ClinGen CA374668001, ClinVar RCV003142630, TOPMed rs2075922654, REVEL 0.36, MetaLR 0.26, Uncertain significance, not provided
- I7V (p.Ile7Val), gnomAD 9-110668923-A-G, REVEL 0.10, MetaLR 0.15
- P8P (p.Pro8Pro), rs1489453069, gnomAD 9-110668928-A-G, CADD 14.00
- L9V (p.Leu9Val), gnomAD rs1257828480, REVEL 0.40, MetaLR 0.31
- V10V (p.Val10Val), rs752539984, gnomAD 9-110668934-A-G, CADD 11.30
- H11R (p.His11Arg), TOPMed rs2075922938, REVEL 0.21, MetaLR 0.18
- I12T (p.Ile12Thr), gnomAD 9-110668939-T-C, REVEL 0.28, MetaLR 0.22
- L13L (p.Leu13Leu), gnomAD 9-110668943-T-C, CADD 10.70
- T14Y (p.Thr14Tyr), gnomAD 9-110668941-C-CT, CADD 32.00
- T14N (p.Thr14Asn), rs863223335, gnomAD 9-110668943-T-TA, CADD 26.10
- T14I (p.Thr14Ile), gnomAD 9-110668945-C-T, REVEL 0.15, MetaLR 0.26
- T14T (p.Thr14Thr), gnomAD 9-110668946-T-C, CADD 11.10
- L15M (p.Leu15Met), rs746254848, ClinGen CA5183895, ClinVar RCV001361316, ClinVar RCV005634106, REVEL 0.34, MetaLR 0.36, Uncertain significance, Fetal akinesia deformation sequence 1; Congenital myasthenic syndrome 9; not pro
- L15P (p.Leu15Pro), Ensembl rs1425561584, REVEL 0.52, MetaLR 0.39
- L15L (p.Leu15Leu), gnomAD 9-110668947-C-T, CADD 11.50
- V16L (p.Val16Leu), rs765521756, NCI-TCGA Cosmic COSV5189, cosmic curated COSV51894, ExAC rs765521756, REVEL 0.09, MetaLR 0.18, Uncertain significance, Inborn genetic diseases
- V16F (p.Val16Phe), gnomAD 9-110668950-G-T, REVEL 0.25, MetaLR 0.27
- V16I (p.Val16Ile), gnomAD 9-110668950-G-A, REVEL 0.10, MetaLR 0.22
- V16A (p.Val16Ala), gnomAD 9-110668951-T-C, REVEL 0.14, MetaLR 0.13
- S19R (p.Ser19Arg), NCI-TCGA Cosmic COSV9950, cosmic curated COSV99504, REVEL 0.50, MetaLR 0.35, Uncertain significance, Inborn genetic diseases
- S19G (p.Ser19Gly), gnomAD 9-110668959-A-G, REVEL 0.16, MetaLR 0.21
- S19S (p.Ser19Ser), rs750615817, gnomAD 9-110668961-C-T, CADD 11.10
- G20* (p.Gly20Ter), ExAC rs758427621, TOPMed rs758427621, gnomAD rs758427621, CADD 35.00, Uncertain significance
- G20R (p.Gly20Arg), rs758427621, ClinGen CA5183898, NCI-TCGA Cosmic COSV5188, cosmic curated COSV51889, REVEL 0.20, MetaLR 0.21, Uncertain significance, Congenital myasthenic syndrome 9; Fetal akinesia deformation sequence 1
- T21A (p.Thr21Ala), ExAC rs747473837, gnomAD rs747473837, REVEL 0.13, MetaLR 0.12
- T21T (p.Thr21Thr), rs1466148518, gnomAD 9-110668967-T-C, CADD 7.98
- E22D (p.Glu22Asp), Ensembl rs2075923369, REVEL 0.30, MetaLR 0.20
- E22K (p.Glu22Lys), NCI-TCGA Cosmic COSV5189, cosmic curated COSV51894, REVEL 0.34, MetaLR 0.34, Variant assessed as somatic; moderate impact.
- K23E (p.Lys23Glu), gnomAD 9-110668971-A-G, REVEL 0.20, MetaLR 0.21
- L24F (p.Leu24Phe), gnomAD 9-110668973-AC-A, CADD 32.00
- L24P (p.Leu24Pro), gnomAD 9-110668975-T-C, REVEL 0.54, MetaLR 0.44
- P25L (p.Pro25Leu), TOPMed rs1332419631, gnomAD rs1332419631, REVEL 0.20, MetaLR 0.23
- P25R (p.Pro25Arg), TOPMed rs1332419631, gnomAD rs1332419631, REVEL 0.34, MetaLR 0.22
- K26N (p.Lys26Asn), TOPMed rs2075923517, MetaLR 0.24, MetaSVM -0.55
- K26E (p.Lys26Glu), gnomAD 9-110668980-A-G, REVEL 0.28, MetaLR 0.20
- A27G (p.Ala27Gly), rs56054734, UniProt VAR 041748, Ensembl rs56054734, REVEL 0.15, MetaLR 0.18
- A27A (p.Ala27Ala), gnomAD 9-110682675-T-A, CADD 9.99
- P28A (p.Pro28Ala), cosmic curated COSV10873, Ensembl rs2131656266
- P28L (p.Pro28Leu), rs2490566494, ClinGen CA374669673, ClinVar RCV002909253, Uncertain significance, Congenital myasthenic syndrome 9; Fetal akinesia deformation sequence 1
- P28P (p.Pro28Pro), rs778144783, gnomAD 9-110682678-T-C, CADD 11.10
- V29A (p.Val29Ala), rs748900538, NCI-TCGA Cosmic COSV5188, cosmic curated COSV51885, ExAC rs748900538, REVEL 0.15, MetaLR 0.19, Variant assessed as somatic; moderate impact.
- I30L (p.Ile30Leu), Ensembl rs2076148348, MetaLR 0.37, MetaSVM -0.52
- I30V (p.Ile30Val), gnomAD 9-110682682-A-G, REVEL 0.35, MetaLR 0.34
- T31A (p.Thr31Ala), gnomAD rs2076148381, REVEL 0.13, MetaLR 0.11
- T32I (p.Thr32Ile), gnomAD rs1248339762, REVEL 0.35, MetaLR 0.38
- T32N (p.Thr32Asn), gnomAD 9-110682689-C-A, REVEL 0.16, MetaLR 0.39
- T32T (p.Thr32Thr), gnomAD 9-110682690-T-A, CADD 10.10
- P33L (p.Pro33Leu), TOPMed rs1254646159, gnomAD rs1254646159, REVEL 0.11, MetaLR 0.20
- P33S (p.Pro33Ser), NCI-TCGA Cosmic COSV5188, cosmic curated COSV51889, REVEL 0.19, MetaLR 0.35, Variant assessed as somatic; moderate impact.
- P33R (p.Pro33Arg), gnomAD 9-110682692-C-G, REVEL 0.30, MetaLR 0.34
- L34V (p.Leu34Val), NCI-TCGA Cosmic COSV9950, MetaLR 0.20, MetaSVM -0.86, Variant assessed as somatic; moderate impact.
- L34L (p.Leu34Leu), rs368035058, gnomAD 9-110682696-T-G, CADD 7.01
- E35A (p.Glu35Ala), Ensembl rs2076148587
- E35K (p.Glu35Lys), rs1485024100, NCI-TCGA Cosmic COSV9950, cosmic curated COSV99505, Ensembl rs1485024100, AlphaMissense 0.29, MetaLR 0.30, Variant assessed as somatic; moderate impact.
- E35Q (p.Glu35Gln), gnomAD 9-110682697-G-C, REVEL 0.33, MetaLR 0.32
- T36I (p.Thr36Ile), gnomAD rs1187922371, REVEL 0.33, MetaLR 0.44
- T36K (p.Thr36Lys), gnomAD 9-110682698-A-AGA, CADD 32.00
- T36T (p.Thr36Thr), rs773795010, gnomAD 9-110682702-A-G, CADD 4.22
- V37A (p.Val37Ala), ExAC rs745336025, TOPMed rs745336025, gnomAD rs745336025, REVEL 0.33, MetaLR 0.41
- V37V (p.Val37Val), rs771663365, gnomAD 9-110682705-G-A, CADD 9.07
- D38E (p.Asp38Glu), rs775587809, ClinGen CA5183928, ClinVar RCV003802057, ClinVar RCV005407260, REVEL 0.71, MetaLR 0.20, Likely pathogenic, Congenital myasthenic syndrome 9; Fetal akinesia deformation sequence 1; MUSK-re
- D38Y (p.Asp38Tyr), rs1412657094, ClinGen CA374669811, ClinVar RCV002269798, gnomAD rs1412657094, REVEL 0.66, MetaLR 0.34, Likely pathogenic, Fetal akinesia deformation sequence 1
- D38D (p.Asp38Asp), gnomAD 9-110682708-T-C, CADD 7.10
- A39T (p.Ala39Thr), NCI-TCGA TCGA novel, MetaLR 0.32, MetaSVM -0.63, Variant assessed as somatic; moderate impact.
- A39V (p.Ala39Val), gnomAD 9-110682710-C-T, REVEL 0.10, MetaLR 0.10
- L40S (p.Leu40Ser), rs901935734, ClinGen CA198335371, ClinVar RCV002776209, ClinVar RCV004948777, REVEL 0.12, MetaLR 0.14, Uncertain significance, Congenital myasthenic syndrome 9; Fetal akinesia deformation sequence 1; Inborn
- V41A (p.Val41Ala), ExAC rs760628267, gnomAD rs760628267, REVEL 0.13, MetaLR 0.11
- V41F (p.Val41Phe), NCI-TCGA TCGA novel, MetaLR 0.19, MetaSVM -0.81, Variant assessed as somatic; moderate impact.
- E42Q (p.Glu42Gln), NCI-TCGA Cosmic COSV5188, cosmic curated COSV51882, MetaLR 0.34, MetaSVM -0.51, Variant assessed as somatic; moderate impact.
- E43D (p.Glu43Asp), rs2131656584, ClinGen CA374669918, NCI-TCGA Cosmic COSV5189, cosmic curated COSV51898, AlphaMissense 0.22, MetaLR 0.05, Uncertain significance, Congenital myasthenic syndrome 9; Fetal akinesia deformation sequence 1
- V44A (p.Val44Ala), rs2076148894, ClinGen CA374669933, ClinVar RCV001166345, Ensembl rs2076148894, AlphaMissense 0.21, MetaLR 0.14, Uncertain significance, Congenital myasthenic syndrome 9
- V44E (p.Val44Glu), gnomAD 9-110682725-T-A, REVEL 0.27, MetaLR 0.10
- V44V (p.Val44Val), gnomAD 9-110682726-G-A, CADD 7.26
- A45P (p.Ala45Pro), rs763800237, ClinGen CA5183930, ClinVar RCV001872649, ExAC rs763800237, REVEL 0.55, MetaLR 0.39, Uncertain significance, Fetal akinesia deformation sequence 1; Congenital myasthenic syndrome 9
- A45V (p.Ala45Val), gnomAD 9-110682728-C-T, REVEL 0.28, MetaLR 0.14
- T46I (p.Thr46Ile), TOPMed rs1319209652, gnomAD rs1319209652, REVEL 0.19, MetaLR 0.19
- T46N (p.Thr46Asn), TOPMed rs1319209652, gnomAD rs1319209652, MetaLR 0.21, MetaSVM -0.76
- T46S (p.Thr46Ser), TOPMed rs1319209652, gnomAD rs1319209652, REVEL 0.05, MetaLR 0.14
- T46A (p.Thr46Ala), gnomAD 9-110682730-A-G, REVEL 0.26, MetaLR 0.16
- T46T (p.Thr46Thr), rs776479773, gnomAD 9-110682732-T-C, CADD 9.74
- F47V (p.Phe47Val), gnomAD 9-110682733-T-G, REVEL 0.47, MetaLR 0.17
- F47L (p.Phe47Leu), gnomAD 9-110682735-C-G, REVEL 0.32, MetaLR 0.04
- M48H (p.Met48His), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- M48I (p.Met48Ile), NCI-TCGA Cosmic COSV9950, cosmic curated COSV99504, MetaLR 0.12, MetaSVM -0.98, Variant assessed as somatic; moderate impact.
- M48T (p.Met48Thr), 1000Genomes rs2131656675, REVEL 0.23, MetaLR 0.13
- C49R (p.Cys49Arg), gnomAD rs1435959892, REVEL 0.85, MetaLR 0.67
- C49S (p.Cys49Ser), TOPMed rs2076149117, MetaLR 0.64, MetaSVM 0.52
- C49del (p.Cys49del), gnomAD 9-110682738-GTGT-, CADD 20.70
- C49W (p.Cys49Trp), gnomAD 9-110682741-T-G, REVEL 0.82, MetaLR 0.64
- C49C (p.Cys49Cys), rs2076149149, gnomAD 9-110682741-T-C, CADD 12.30
- p.Ala50 Val51insThrPheLeu, gnomAD 9-110682743-C-CTA, CADD 18.50
- A50A (p.Ala50Ala), gnomAD 9-110682744-A-C, CADD 9.21
- V51V (p.Val51Val), gnomAD 9-110682747-G-T, CADD 10.30
- E52A (p.Glu52Ala), rs1554732832, ClinGen CA374670074, ClinVar RCV000518524, Ensembl rs1554732832, AlphaMissense 0.36, MetaLR 0.32, Uncertain significance, not specified
- E52E (p.Glu52Glu), gnomAD 9-110682750-A-G, CADD 11.90
- E52D (p.Glu52Asp), gnomAD 9-110682750-A-T, REVEL 0.09, MetaLR 0.12
- S53E (p.Ser53Glu), gnomAD 9-110682750-A-AGA, CADD 31.00
- S53A (p.Ser53Ala), gnomAD 9-110682751-T-G, REVEL 0.16, MetaLR 0.13
- p.Ser53 Tyr54insTer, gnomAD 9-110682752-C-CAT, CADD 33.00
- S53F (p.Ser53Phe), gnomAD 9-110682752-C-T, REVEL 0.43, MetaLR 0.42
- Y54* (p.Tyr54Ter), TOPMed rs2076149264, CADD 32.00, Likely benign
- Y54D (p.Tyr54Asp), ExAC rs763142796, TOPMed rs763142796, gnomAD rs763142796, REVEL 0.25, MetaLR 0.17
- Y54H (p.Tyr54His), NCI-TCGA TCGA novel, MetaLR 0.27, MetaSVM -0.70, Variant assessed as somatic; moderate impact.
- P55S (p.Pro55Ser), NCI-TCGA Cosmic COSV9950, cosmic curated COSV99504, MetaLR 0.70, MetaSVM 0.62, Variant assessed as somatic; moderate impact.
- P55A (p.Pro55Ala), gnomAD 9-110682757-C-G, REVEL 0.80, MetaLR 0.67
- P55P (p.Pro55Pro), rs766600402, gnomAD 9-110682759-C-T, CADD 4.13
- Q56K (p.Gln56Lys), NCI-TCGA Cosmic COSV5187, NCI-TCGA Cosmic COSV9950, cosmic curated COSV99505, MetaLR 0.09, MetaSVM -0.92, Variant assessed as somatic; moderate impact.
- Q56E (p.Gln56Glu), gnomAD 9-110682760-C-G, REVEL 0.07, MetaLR 0.09
- P57A (p.Pro57Ala), Ensembl rs2076149293, REVEL 0.10, MetaLR 0.25
- P57P (p.Pro57Pro), gnomAD 9-110682765-T-G, CADD 9.24
- E58Q (p.Glu58Gln), NCI-TCGA TCGA novel, MetaLR 0.35, MetaSVM -0.42, Variant assessed as somatic; moderate impact.
- I59N (p.Ile59Asn), gnomAD 9-110682770-T-A, REVEL 0.66, MetaLR 0.48
- I59T (p.Ile59Thr), gnomAD 9-110682770-T-C, REVEL 0.60, MetaLR 0.44
- S60F (p.Ser60Phe), TOPMed rs1310418682
- S60S (p.Ser60Ser), gnomAD 9-110682774-C-T, CADD 8.97
- T62I (p.Thr62Ile), ExAC rs751680282, TOPMed rs751680282, gnomAD rs751680282, REVEL 0.19, AlphaMissense 0.31
- T62N (p.Thr62Asn), rs751680282, ExAC rs751680282, TOPMed rs751680282, gnomAD rs751680282, AlphaMissense 0.31, MetaLR 0.24, Variant assessed as somatic; moderate impact.
- N64S (p.Asn64Ser), gnomAD 9-110682785-A-G, REVEL 0.26, MetaLR 0.13
- I66F (p.Ile66Phe), gnomAD 9-110682790-A-T, REVEL 0.17, MetaLR 0.17
- I66T (p.Ile66Thr), gnomAD 9-110682791-T-C, REVEL 0.18, MetaLR 0.13
- I66I (p.Ile66Ile), rs567402281, gnomAD 9-110682792-T-C, CADD 12.00
- L67H (p.Leu67His), TOPMed rs752882699, gnomAD rs752882699, REVEL 0.24, MetaLR 0.27
- L67I (p.Leu67Ile), NCI-TCGA Cosmic COSV9950, cosmic curated COSV99504, REVEL 0.16, MetaLR 0.24, Variant assessed as somatic; moderate impact.
- L67P (p.Leu67Pro), TOPMed rs752882699, gnomAD rs752882699, MetaLR 0.09, MetaSVM -1.02
- L67L (p.Leu67Leu), gnomAD 9-110682795-C-A, CADD 7.67
- I68F (p.Ile68Phe), gnomAD rs1322165872, REVEL 0.47, MetaLR 0.22
- I68N (p.Ile68Asn), TOPMed rs2076149536, MetaLR 0.54, MetaSVM 0.16
- I68del (p.Ile68del), rs1417996565, gnomAD 9-110682795-CATT-, CADD 19.10
- K69E (p.Lys69Glu), TOPMed rs2076149604, MetaLR 0.16, MetaSVM -0.87
- K69N (p.Lys69Asn), rs2076206381, ClinGen CA374664144, ClinVar RCV001943666, gnomAD rs2076206381, REVEL 0.16, MetaLR 0.22, Uncertain significance, Fetal akinesia deformation sequence 1; Congenital myasthenic syndrome 9
- L70F (p.Leu70Phe), NCI-TCGA Cosmic COSV9950, cosmic curated COSV99504, Ensembl rs2076206441, REVEL 0.13, MetaLR 0.24, Variant assessed as somatic; moderate impact.
- L70P (p.Leu70Pro), TOPMed rs2076206496, REVEL 0.18, MetaLR 0.13
- L70V (p.Leu70Val), Ensembl rs2076206441, MetaLR 0.14, MetaSVM -0.97
- L70L (p.Leu70Leu), gnomAD 9-110687120-C-A, CADD 8.34
- F71V (p.Phe71Val), Ensembl rs2076206609, REVEL 0.38, MetaLR 0.32
- F71L (p.Phe71Leu), gnomAD 9-110687121-T-C, REVEL 0.33, MetaLR 0.25
- F71F (p.Phe71Phe), gnomAD 9-110687123-T-C, CADD 11.90
- D72E (p.Asp72Glu), TOPMed rs2076206669, MetaLR 0.13, MetaSVM -0.87
- D72* (p.Asp72Ter), gnomAD 9-110687120-C-CT, CADD 32.00
- D72H (p.Asp72His), gnomAD 9-110687124-G-C, REVEL 0.47, MetaLR 0.25
- D72Y (p.Asp72Tyr), gnomAD 9-110687124-G-T, REVEL 0.63, MetaLR 0.26
- T73A (p.Thr73Ala), rs1021042074, ClinGen CA198337252, ClinVar RCV003193518, TOPMed rs1021042074, REVEL 0.15, MetaLR 0.06, Uncertain significance, Inborn genetic diseases
- T73I (p.Thr73Ile), rs750101214, ClinGen CA374664190, ClinVar RCV000653235, ExAC rs750101214, AlphaMissense 0.56, MetaLR 0.20, Uncertain significance, Fetal akinesia deformation sequence 1; Congenital myasthenic syndrome 9
- T73N (p.Thr73Asn), ExAC rs750101214, gnomAD rs750101214, REVEL 0.18, AlphaMissense 0.56, Uncertain significance
- T73S (p.Thr73Ser), TOPMed rs1021042074, gnomAD rs1021042074, REVEL 0.10, MetaLR 0.04, Uncertain significance
- T73T (p.Thr73Thr), rs2076206983, gnomAD 9-110687129-C-A, CADD 7.15
- R74G (p.Arg74Gly), TOPMed rs1370203787, gnomAD rs1370203787, REVEL 0.39, MetaLR 0.29, Uncertain significance
- R74L (p.Arg74Leu), ExAC rs758118087, TOPMed rs758118087, gnomAD rs758118087, MetaLR 0.35, MetaSVM -0.37, Uncertain significance
- R74Q (p.Arg74Gln), rs758118087, ClinGen CA5183966, cosmic curated COSV51886, ClinVar RCV001927832, REVEL 0.43, MetaLR 0.30, Uncertain significance, Fetal akinesia deformation sequence 1; Congenital myasthenic syndrome 9
- R74W (p.Arg74Trp), rs1370203787, ClinGen CA374664194, ClinVar RCV002025719, TOPMed rs1370203787, REVEL 0.48, MetaLR 0.39, Uncertain significance, Fetal akinesia deformation sequence 1; Congenital myasthenic syndrome 9; not spe
- R74P (p.Arg74Pro), gnomAD 9-110687131-G-C, REVEL 0.54, MetaLR 0.33
- Y75S (p.Tyr75Ser), ExAC rs779767402, REVEL 0.65, MetaLR 0.50
- Y75Y (p.Tyr75Tyr), rs56130155, gnomAD 9-110687135-C-T, CADD 9.56
- S76I (p.Ser76Ile), gnomAD rs1352178393, REVEL 0.15, MetaLR 0.21
- S76N (p.Ser76Asn), rs1352178393, NCI-TCGA Cosmic COSV9950, cosmic curated COSV99504, gnomAD rs1352178393, REVEL 0.11, MetaLR 0.28, Variant assessed as somatic; moderate impact.
- S76S (p.Ser76Ser), rs768514590, gnomAD 9-110687138-C-T, CADD 12.30
- I77T (p.Ile77Thr), rs547322569, ClinGen CA5183969, ClinVar RCV002040882, ClinVar RCV002548857, REVEL 0.15, MetaLR 0.26, Uncertain significance, Fetal akinesia deformation sequence 1; Congenital myasthenic syndrome 9; Inborn
- I77I (p.Ile77Ile), gnomAD 9-110687141-C-T, CADD 8.05
- R78Q (p.Arg78Gln), rs776815006, ClinGen CA5183971, ClinVar RCV000341644, ClinVar RCV001217123, REVEL 0.15, MetaLR 0.09, Uncertain significance, Inborn genetic diseases; not provided; Fetal akinesia deformation sequence 1
Public MUSK analysis runs
- MUSK analysis run — MUSK (1,398 variants) — completed 2026-08-22